相关实验视频

Updated: May 7, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

用于复发或耐药的外围T细胞淋巴瘤 (VALENTINE-PTCL01) 患者的瓦莱梅托斯塔特:多中心,开放标签,单臂,第二阶段研究

Pier Luigi Zinzani¹, Koji Izutsu², Neha Mehta-Shah³

¹Lymphoma and Chronic Lymphoproliferative Syndromes Unit, Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.

The Lancet. Oncology

|November 1, 2024

概括

在患有复发或耐药的外围T细胞淋巴瘤的患者中,瓦莱梅托斯塔特显示出持久的反应. 这种新型EZH2/EZH1抑制剂在VALENTINE-PTCL01试验中显示出可管理的安全性.

科学领域:

在瘤学瘤学.
血液学血液学血液学
药理学药理学是指药理学的学科.

背景情况:

周围T细胞淋巴瘤 (PTCL) 是一种具有侵略性的非霍奇金淋巴瘤,对于复发性或耐药性疾病的治疗选择有限.
瓦莱梅托斯酸是一种针对EZH2和EZH1酶的新型双重抑制剂.
研究了valemetostat在PTCL和成人T细胞白血病/淋巴瘤 (ATLL) 的临床活性和安全性.

研究的目的:

评估valemetostat在患有复发或耐药PTCL的患者中的疗效和安全性.
评估瓦莱梅托斯塔特在复发性或耐火性ATLL患者的安全性和耐受性.

主要方法:

一个多中心,开放标签,单臂,第二阶段试验 (VALENTINE-PTCL01) 招募了18岁以上的患者,ECOG性能状态为0-2.
患者每天服用口服valemetostat200毫克,直到疾病进展或毒性.
PTCL的主要疗效终点是BICR的客观反应率 (ORR);ATLL的主要安全终点是安全性和耐受性.

主要成果:

纳入了133名复发/耐药PTCL患者和22名ATLL患者.
在可有效性评估的PTCL患者中,客观应答率 (ORR) 为44% (95%CI 35-53).
最常见的3-4级不良事件包括血小板缺血 (23%PTCL,50%ATLL),贫血 (19%PTCL,46%ATLL) 和中性质缺血 (17%PTCL,18%ATLL). 严重的治疗不良事件发生在40%的PTCL患者和68%的ATLL患者中.

结论:

在患有复发性或耐火性PTCL的患者中,valemetostat治疗导致了持久的反应.
在研究的患者群体中,valemetostat的安全性概况是可控的.
这些发现支持valemetostat作为PTCL的潜在治疗选择.

更多相关视频

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

Measurement of Mitochondrial Mass and Membrane Potential in Hematopoietic Stem Cells and T-cells by Flow Cytometry

Measurement of Mitochondrial Mass and Membrane Potential in Hematopoietic Stem Cells and T-cells by Flow Cytometry

Published on: December 26, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...